Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM)

3Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Introduction: Safranal is an active component of the traditional Tibetan medicine (TTM) saffron, which has potential anticancer activity. Methods and results: Here, we studied the therapeutic effect and mechanism of safranal on GBM. CCK-8, GBM-brain organoid coculture experiments and 3D tumour spheroid invasion assays showed that safranal inhibited GBM cell proliferation and invasion in vitro. Network pharmacology, RNA-seq, molecular docking analysis, western blotting, apoptosis, and cell cycle assays predicted and verified that safranal could promote GBM cell apoptosis and G2/M phase arrest and inhibit the PI3K/AKT/mTOR axis. In vivo experiments showed that safranal could inhibit GBM cell growth alone and in combination with TMZ. Conclusion: This study revealed that safranal inhibits GBM cell growth in vivo and in vitro, promotes GBM cell apoptosis and G2/M phase arrest, inhibits the PI3K/AKT/mTOR axis and cooperate with TMZ.

Cite

CITATION STYLE

APA

Yang, X., Lu, D., Sun, Y., Wei, T., Man, D., Chen, A., … Li, X. (2023). Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM). Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1255164

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free